Screener
Protagonist Therapeutics PTGX Business Segments — Employee Expense Benefit Related To Discovery
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept ptgx:EmployeeExpenseBenefitRelatedToDiscovery.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Discovery department expense (1)(2) | (8,521) | (4,952) | (17,027) | (8,698) |
| Development department expense (1)(2) | (14,432) | (15,504) | (31,905) | (28,409) |
| General and administrative expenses (1) | (5,745) | (5,890) | (11,440) | (11,425) |
| Employee wages and benefits - discovery (2) | (2,668) | (2,188) | (5,816) | (4,515) |
| Employee wages and benefits - development (2) | (4,949) | (4,658) | (10,901) | (10,142) |
| Employee wages and benefits - general and administrative | (4,357) | (3,483) | (9,080) | (7,315) |
| Stock-based compensation expense | (14,037) | (10,912) | (28,556) | (24,714) |
| Other segment items (3) | (81) | 36 | (28) | 118 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's business segments — employee expense benefit related to discovery?
- Protagonist Therapeutics (PTGX) reported business segments — employee expense benefit related to discovery of $2.67M in Q2 2026.
- How has Protagonist Therapeutics's business segments — employee expense benefit related to discovery changed year-over-year?
- Protagonist Therapeutics's business segments — employee expense benefit related to discovery increased by 21.9% year-over-year, from $2.19M to $2.67M.
- What is the long-term trend for Protagonist Therapeutics's business segments — employee expense benefit related to discovery?
- Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — employee expense benefit related to discovery has grown at a 17.0% compound annual growth rate (CAGR), from $6.16M to $9.88M.
- What does business segments — employee expense benefit related to discovery mean?
- This represents the total cash-based compensation and benefits provided to personnel directly involved in the discovery phase of drug development. It reflects the investment in human capital required to maintain the company's proprietary technology platform. Changes in this metric indicate shifts in the size or cost of the research team dedicated to early-stage innovation.
Ask your AI about Protagonist Therapeutics's business segments — employee expense benefit related to discovery.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude